PMID- 33928100
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210502
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 8
DP  - 2021
TI  - Erythropoietin Attenuates Experimental Contrast-Induced Nephrology: A Role for 
      the Janus Kinase 2/Signal Transducer and Activator of Transcription 3 Signaling 
      Pathway.
PG  - 634882
LID - 10.3389/fmed.2021.634882 [doi]
LID - 634882
AB  - The aim of the present study was to investigate the effect of erythropoietin 
      (EPO) on contrast-induced nephrology (CIN) in vivo and in vitro. Male C57BL/6J 
      mice were divided into four groups: control, CIN (iohexol 6.0 g/kg), EPO (3,000 
      IU/kg), and CIN+EPO. Hematoxylin and eosin (H&E) staining and biochemical index 
      analyses were performed to evaluate renal injury. The cellular proliferation rate 
      was detected using the Cell Counting Kit-8 (CCK-8) assay. In addition, a terminal 
      deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay and 
      flow cytometric assay were used to assess the apoptosis of tissue and cells, 
      respectively. Renal protein expression associated with apoptosis, pyroptosis, and 
      signaling pathways was determined by Western blot (WB) assays for tissues and 
      cells. The results showed that EPO significantly decreased serum creatinine, 
      blood urea nitrogen, and cystatin C levels and alleviated renal histological 
      changes in vivo. The protein levels of Janus kinase 2/signal transducer and 
      activator of transcription 3 (JAK2/STAT3) signaling pathway components were 
      overexpressed in the EPO treatment group. Furthermore, EPO suppressed the cell 
      apoptosis and pyroptosis; decreased the protein levels of cleaved caspase-3, Bax, 
      gasdermin D (GSDMD), and caspase-1; and enhanced the expression of Bcl-2. In 
      summary, EPO could exert renoprotective effect by activating the JAK2/STAT3 
      signaling pathway, which may be a novel potential therapy for the treatment of 
      CIN in the clinic.
CI  - Copyright (c) 2021 Yang, Zhou, Wang, Ji, Wang, Chen and Yang.
FAU - Yang, Jia
AU  - Yang J
AD  - Division of Nephrology, Department of Medicine, West China Hospital of Sichuan 
      University, Chengdu, China.
FAU - Zhou, Jiaojiao
AU  - Zhou J
AD  - Division of Ultrasound, West China Hospital of Sichuan University, Chengdu, 
      China.
FAU - Wang, Xin
AU  - Wang X
AD  - Department of Pediatric Nephrology, West China Second University Hospital, 
      Sichuan University, Chengdu, China.
FAU - Ji, Ling
AU  - Ji L
AD  - Division of Nephrology, Department of Medicine, West China Hospital of Sichuan 
      University, Chengdu, China.
FAU - Wang, Siwen
AU  - Wang S
AD  - Division of Nephrology, Department of Medicine, West China Hospital of Sichuan 
      University, Chengdu, China.
FAU - Chen, Xuelian
AU  - Chen X
AD  - Division of Nephrology, Department of Medicine, West China Hospital of Sichuan 
      University, Chengdu, China.
FAU - Yang, Lichuan
AU  - Yang L
AD  - Division of Nephrology, Department of Medicine, West China Hospital of Sichuan 
      University, Chengdu, China.
LA  - eng
PT  - Journal Article
DEP - 20210413
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC8076515
OTO - NOTNLM
OT  - JAK2
OT  - apoptosis
OT  - contrast-induced nephrology
OT  - erythropietin
OT  - stat3
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/05/01 06:00
MHDA- 2021/05/01 06:01
PMCR- 2021/04/13
CRDT- 2021/04/30 06:56
PHST- 2020/11/29 00:00 [received]
PHST- 2021/02/15 00:00 [accepted]
PHST- 2021/04/30 06:56 [entrez]
PHST- 2021/05/01 06:00 [pubmed]
PHST- 2021/05/01 06:01 [medline]
PHST- 2021/04/13 00:00 [pmc-release]
AID - 10.3389/fmed.2021.634882 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2021 Apr 13;8:634882. doi: 10.3389/fmed.2021.634882. 
      eCollection 2021.